Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: Do children of all ages respond equally?
Authors:
- Emmanuel B. WalterEWEmmanuel B. Walter
- Shilpa RajagopalSRShilpa Rajagopal
- Yuwei ZhuYZYuwei Zhu
- Kathleen M. NeuzilKNKathleen M. Neuzil
- Mary P. FairchokMFMary P. Fairchok
- Janet A. EnglundJEJanet A. Englund
- 17 June 2010
- Vol. 28 (27) , 4376-4383
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Trivalent Inactivated Influenza Virus Vaccine Given to Two-Month-Old ChildrenThe Pediatric Infectious Disease Journal, 2009
- Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in InfantsThe Journal of Infectious Diseases, 2008
- Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 seasonThe Journal of Pediatrics, 2006
- Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old ChildrenThe Journal of Infectious Diseases, 2006
- Influenza Vaccine Immunogenicity in 6- to 23-Month-Old Children: Are Identical Antigens Necessary for Priming?Pediatrics, 2006
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Studies of the 1996–1997 Inactivated Influenza Vaccine among Children Attending Day Care: Immunologic Response, Protection against Infection, and Clinical EffectivenessThe Journal of Infectious Diseases, 2000
- Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza virusesEpidemiology and Infection, 1989
- Inactivated vaccines. 2. Laboratory indices of protectionPresented by the senior author before the symposium on Influenza Vaccines, London, 27 April 1972.Postgraduate Medical Journal, 1973
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972